Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree

Executive Summary

The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.


Related Content

AZ China Growth Pops Again But Clouds Loom
Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
AZ Goes Into The MYSTIC And Finds Positives For Imfinzi
EAGLE Crash Lands: AstraZeneca's Imfinzi/Tremelimumab Continues To Disappoint
AstraZeneca's PACIFIC Update Bolsters Imfinzi's Lead In Stage III Lung Cancer
Japan Approval Another Boost For Tagrisso in 1L NSCLC
New EU Approval Further Boost For Tagrisso As Threats Recede


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts